[製剤] Lonza Collaborates with Takeda to Bring Cancer Treatment to Patients

・European Commission approved ALUNBRIG® (brigatinib), once-daily tablet for adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
・The Lonza team in Tampa, FL (USA) collaborated with Takeda to provide support from early drug product development studies through commercial supply to help bring this new cancer treatment to patients.
・ALUNBRIG is already approved by the U.S. Food and Drug Administration (FDA) for use in this setting in the United States
（リンク先より全文をご覧いただけます/英語）

• リリース情報を見る